Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$59 Mln
P/E Ratio
--
P/B Ratio
3.28
Industry P/E
--
Debt to Equity
0.51
ROE
-1.49 %
ROCE
-104.09 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-230.12 Mln
EBITDA
$-290.49 Mln
Net Profit
$-300.97 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
| -23.28 | -15.06 | -30.88 | -46.73 | -42.59 | -48.44 | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Cue Biopharma (CUE)
| -58.41 | -7.37 | -74.80 | -9.59 | -21.20 | 237.77 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.78 | 9,808.03 | 20.22 | 23.13 | |
| 290.25 | 8,956.09 | 22.08 | 58.42 | |
| 26.54 | 9,559.25 | -- | -28.77 | |
| 103.22 | 10,030.35 | 30.81 | 14.16 |
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the... CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts. Address: 40 Guest Street, Boston, MA, United States, 02135 Read more
CEO & Director
Mr. Daniel R. Passeri J.D., M.Sc.
CEO & Director
Mr. Daniel R. Passeri J.D., M.Sc.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cue Biopharma (CUE) stood at $ 32 Mln as on 31-Dec-24
The share price of Cue Biopharma (CUE) is $0.84 (NASDAQ) as of 23-Apr-2025 16:00 EDT. Cue Biopharma (CUE) has given a return of -42.59% in the last 3 years.
Cue Biopharma (CUE) has a market capitalisation of $ 59 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Cue Biopharma (CUE) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cue Biopharma (CUE) and enter the required number of quantities and click on buy to purchase the shares of Cue Biopharma (CUE).
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts. Address: 40 Guest Street, Boston, MA, United States, 02135
The CEO & director of Mr. Daniel R. Passeri J.D., M.Sc.. is Cue Biopharma (CUE), and CFO & Sr. VP is Mr. Daniel R. Passeri J.D., M.Sc..
There is no promoter pledging in Cue Biopharma (CUE).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Cue Biopharma (CUE) | Ratios |
|---|---|
|
Return on equity(%)
|
-149.03
|
|
Operating margin(%)
|
-446.54
|
|
Net Margin(%)
|
-437.97
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cue Biopharma (CUE) was $0 Mln.
$0.05
(
